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Commentary
The development of veterinary oncology as a 
speciality has benefited from the changing role 
of companion animals in society, and the acces-
sibility to treatment afforded by pet insurance 
schemes now means that, at least in financial 
terms, a diagnosis of cancer in our pets is no 
longer an automatic death sentence. Veterinary 
oncology is making significant inroads as a 
specialist field of veterinary internal medicine, 
reflected by the work of referral practices around 
the USA and Europe. Many are affiliated with 
veterinary schools, which are leading the way in 
the development and optimization of treatments 
for a range of veterinary cancers. The Veterinary 
Cancer Society and the European Association of 
Veterinary Oncology have grown into vibrant 
professional organizations to promote advances 
in veterinary oncology. What is particularly 
illuminating is that studies involving sponta-
neous veterinary cancers are now appearing in 
the mainstream cancer research journals – in 
fact, a recent issue of this journal dedicated a 
mini-focus to veterinary pharmaceuticals [1]. 
Historically, efforts to merge the medical and 
veterinary professions towards mutual benefit 
of human and animal species began in the mid 
19th century with the observations of Rudolf 
Virchow; who, being the son of a butcher, was 
well-placed to observe that the similarities 
between man and beast might lead to the trans-
mission of infection. Inspired by these obser-
vations, Virchow became the first to describe 
the concept of zoonoses. It was his colleague, 
William Osler, however, who used these ini-
tial concepts and his interests in comparative 
pathology to turn veterinary pathology into a 
major discipline of the clinical sciences. In the 
process, he was advocating a ‘One Medicine’ 
philosophy that would encourage advances in 
public health and increase our understanding of 
human and veterinary disease. The implications 
are still felt today, where the unravelling of the 
molecular pathogenesis of cross-species diseases, 
such as HIV and cancer, the evolution of drug 
resistance and the use of genetically manipu-
lated animal models in biomedical research may 
be directly attributed to our understanding of 
comparative pathology. In recognition of the 
continuing need for cooperation and a shared 
platform for veterinary and medical research, 
The American Medical Association and the 
American Veterinary Medical Association have 
approved resolutions supporting the bridging 
between the two professions [2].
As we move into the second decade of the 
new millennium, comparative pathology is 
morphing into comparative ‘omics’, where, for 
example, canine cross-species genomics has 
been used to identify gene signatures expressed 
in human and canine osteosarcoma as a means 
of validating canine osteosarcoma as a model 
for the human disease [3]. Organizations such 
as the Veterinary Cancer Registry provide a 
resource for those studying the epidemiology of 
veterinary cancers, whereas sequencing projects 
such as the Canine Genome Project, a collabo-
ration between the University of California, 
Berkeley (CA, USA), the University of Oregon 
(OR, USA), and the Fred Hutchinson Cancer 
Research Center, Seattle, Washington (DC, 
USA); and the Cat Genome Project, based at 
the Laboratory of Genomic Diversity at the 
National Cancer Institute (USA), have also pro-
vided comprehensive data on the expression of 
genes and, therefore, drug targets influential in 
tumorigenesis. This will help initiate studies to 
find new biomarkers, gene signatures and drug 
targets all available for bioinformatic analysis 
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and comparison with data from the Human 
Genome Project.
The development of molecular cytogenetics 
has revealed chromosomal aberrations linked to 
malignant transformation; these have proven to 
be powerful prognostic indicators and a means of 
rationally applying chemotherapy with targeted 
anticancer agents in animal and human species. 
An early example is the Philadelphia chromo-
some, a translocation mutation that leads to over-
expression of the fusion protein bcr–abl, a tyro-
sine kinase linked with tumor cell survival and 
proliferative pathways in chronic myelogenous 
leukemia that is expressed in both human and 
canine versions of the disease. This has enabled 
the leveraging of the bcr–abl inhibitor imatinib 
(Glivec®) for human to veterinary use [4].
There is a wealth of knowledge and experi-
ence to be gained from our veterinary oncology 
colleagues due to the synergy that often exists 
between our species and that of companion 
animals, concentrating particularly on cancers 
such as lymphoma/leukemia, osteosarcoma, 
melanoma and mammary carcinoma [5]. The 
Comparative Oncology Program, a division of 
the US National Institute of Health, proposes a 
scheme whereby studies involving cats and dogs 
are used as an additional layer of preclinical 
data to inform human cancer trials, alongside 
preclinical experimental animal models such 
as xenograft, transgenic or gene-targeted mice 
[6]. There are clear ethical advantages to using 
spontaneous veterinary cancers as models of 
human cancer – decreased reliance on geneti-
cally manipulated rodent models is in keeping 
with the reduction, refinement and replacement 
ethos in research involving laboratory animals. 
Ethical issues aside, however, we have greater 
genetic homology with dogs than with mice, 
they share our environment and therefore our 
risk of exposure to carcinogens unlike transgenic 
mice, there is a degree of genetic heterogene-
ity in the canine and our population. Like our 
cancers, veterinary cancers also occur naturally 
rather than by experimental induction. The 
biological similarities, such as the size, physiol-
ogy and natural history of tumors in cats and 
dogs arguably provide a more relevant model; 
however, there are some double-edged swords. 
Companion animals and humans show similar 
size and tumor volumes, potentially providing 
a clinically valid predictive model for pharma-
cokinetic and toxicological studies. Whereas this 
offers the clear advantage of being able to use 
dose ranges directly translatable to subsequent 
Phase I dose escalation studies carried out in 
humans, the flipside is the consequent increased 
cost of the drug formulations used. 
Another issue to circumvent is that the aver-
age lifespan of the dog allows ‘clinical trials’ 
to take place over a shorter time span than in 
humans, where follow-up times of around 1–3 
years are typically cited. These studies, however, 
will still take longer to complete than those 
involving mouse models [7,8]. That said, in con-
trast to the xenografted tumors often used for 
in vivo testing of anticancer agents, spontaneous 
veterinary cancers are syngeneic, that is, tumor 
and host are matched [9]. In a field where much 
of the scientific workforce is focused on develop-
ing agents that target the interaction between 
tumor cell and the host tissue environment, it is 
crucial that we have models where the molecular 
pathways being targeted are not purely restricted 
to malignant cells, but also to the host systems 
that heavily influence the path of cancer progres-
sion, such as the vasculature, inflammation and 
host immunity.
Veterinary oncology research initially lagged 
behind the rapid pace of human experimental 
and clinical oncology in terms of drug discovery 
and development. For instance, there has been 
a significant amount of catch-up to be done to 
optimize treatment regimens involving classical 
anticancer agents and radiation. These treatment 
modalities are reasonably well established in 
human oncology. Where veterinary oncology is 
coming into its own, however, is that first-in-dog 
studies care now a viable route for the preclinical 
development of novel targeted agents.  
Where veterinary oncology potentially comes 
into its own as a model is for rare human can-
cers, about which we know relatively little. For 
instance, the incidence of osteosarcoma, a high-
grade primary bone tumor, is only 1–3 cases per 
million worldwide and tends to affect teenag-
ers and young adults. In contrast, osteosarcoma 
is a relatively common type of cancer in dogs, 
where approximately 8000 dogs per year are reg-
istered with the disease in the USA. While osteo-
sarcoma is a disease of older dogs, as in humans 
the tumor tends to occur in the metaphyseal sec-
tion of long bones. The underlying molecular 
pathogenesis is similar in part – p53 mutations 
arise in both canine and human osteosarcoma 
and, just as HER-2 overexpression is an indi-
cator of poor prognosis in the human disease, the 
related erb-b2 gene is overexpressed in the canine 
disease. The similarity extends to the expression 
of PDGFR, the IGF-1 receptor and oncogenes 
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such as c-myc. In terms of the natural history of 
the disease, the pattern of metastasis also shows 
similarity, most commonly occurring in the lung 
[8]. A canine brief-pain inventory has proven to 
be a reliable device when measuring pain con-
structs and interference with normal activity, 
showing potential for use in pain studies that 
will optimize how we clinically manage bone 
pain and assess quality of life in the palliative 
care of human patients with the disease [10].
Canine mammary gland cancers are also 
considered to be models of human breast can-
cer and, accordingly, biomarker studies have 
revealed shared molecular pathways involving 
the over expression of steroid receptors, prolif-
eration markers, mutated p53 and microenvi-
ronmental targets, such as the matrix metallo-
proteinases and cyclooxygenases. Human and 
canine diseases have a similar clinical course, 
hormone-dependent etiology and relative age 
of onset [11]. Some important comparative stud-
ies taking place at the veterinary school at the 
Freie Universität Berlin (Germany) have looked 
at the shared characteristics of metastastatic 
breast disease at the genomic, proteomic and 
transcriptomic level. In particular, the tran-
scriptomic study revealed a metastatic ‘cascade’ 
of pathways relating to cell division and matrix 
invasion. Again, upregulation of matrix metal-
loproteinases was observed in metastatic tumors 
alongside downregulation of adhesion proteins 
such as PECAM1, demon strating an overlap 
with gene expression signatures in human breast 
cancer [12]. 
To be able to realistically integrate clinical trial 
data from veterinary patients with human stud-
ies depends upon the use of comparable clinical 
end points and being able to ‘scale’ these appro-
priately. Response Evaluation Criteria in Solid 
Tumors guidelines are continually updated in 
both human and veterinary cancers by consensus, 
considering parameters such as the measurable 
size of the lesion and how this relates to the extent 
of response and disease progression after treat-
ment. Although, of course, timescales involved 
and the point at which response is evaluated 
differs between veterinary and human patients, 
the approach is similar, where time to progres-
sion may be used as a parameter for evaluation 
of clinical response in trials [13]. The diagnostic 
approaches typically used in human oncology tri-
als, such as 18FDG PET, are also gaining accept-
ance in veterinary oncology; a good example 
being its use to assess response to the tyrosine 
kinase inhibitor tocaranib, a newly approved 
targeted anticancer agent specifically licensed 
for the treatment of canine mast cell tumors [14]. 
The development of tyrosine kinase inhibitors 
is perhaps the biggest success story for targeted 
anticancer agents in both veterinary and human 
oncology. As well as promising data coming out 
of trials of imatinib in dogs and cats with mast 
cell tumors and sarcomas, the recent approval of 
tocarenib (Palladia®) and masitinib (Masivet®), 
also for the treatment of canine mast cell tumors, 
is testament to the investment in veterinary 
oncology by the pharmaceutical industry and 
the laying of groundwork for future trials as 
part of multimodality treatments in companion 
animals. Imatinib was originally developed as a 
novel treatment for bcr-abl-expressing chronic 
myleogenous leukemia, subsequent studies 
highlighted its activity against the oncogene 
c-Kit in gatrointestinal stromal tumors [15] and 
melanomas arising in humans [16]. Crucially, 
however, tocarenib and masitinib were developed 
for veterinary patients. Kit is a mast cell receptor, 
where its mutation leads to excessive signalling 
and loss of growth control. Tocarenib is a multi-
kinase inhibitor, targeting Kit, but also VEGFR, 
PDGFR and Flt-3; and, aside from its current 
use for canine mast cell tumors, the drug has 
been evaluated in a range of other tumor types 
such as sarcomas, carcinomas, melanoma and 
myeloma [17]. What is particularly interesting 
here is that the uptake of these agents demon-
strates that angiogenic growth factor receptors, 
such as EGFR and VEGF, are of shared promi-
nence in human and veterinary research, and 
that there is scope for leveraging trials involving 
novel tyrosine kinase inhibitors from veterinary 
to human medicines and vice versa. As far as Kit 
goes, however, the relevance of the target relates 
to the differences in tumor pathology existing 
between man and companion animals. Mast cell 
tumors are a relatively common malignancy in 
dogs, particularly Boxers, that tend to develop in 
the skin and intestines; whereas, the most closely 
related condition in man is mastocytosis, a con-
dition that may manifest cutaneously as mas-
tocytoma of the skin, but has mainly systemic 
effects affecting mast cell function throughout 
the body. Both mast cell tumors in companion 
animals and mastocytosis as it occurs in humans 
are mediated via activation of Kit. Masitinib, like 
tocaranib and imatinib, targets Kit. Accordingly, 
masitinib is now being transferred to human 
oncology, where it is undergoing evaluation as 
a treatment for mast cell leukemia, which is one 
manifestation of mastocytosis [18,19].   
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Although it has taken decades of human oncol-
ogy research to produce the targeted agents, this 
knowledge has been rapidly taken up by the vet-
erinary oncology field and we have seen tyrosine 
kinase inhibitors for veterinary use developed in 
parallel with their human equivalents. In a simi-
lar fashion, ‘hot topics’ currently on the human 
oncology research circuit, such as the tumor 
microenvironment, metabolism and radiation 
oncology, are experiencing a knowledge surge in 
veterinary oncology. For instance, work is cur-
rently taking place at the Comparative Oncology 
Program to bring inhibitors of the mammalian 
target of rapamycin (mTOR) into clinical use 
for canine osteosarcoma [20]. We are also seeing 
clinical trials to evaluate novel agents targeting 
the molecular chaperone Hsp90 in dogs with a 
range of spontaneous tumors, which is parallel to 
the development of Hsp90 inhibitors in human 
oncology research [21]. 
While to any pet owner, the successful treat-
ment and prolongation of life for our canine and 
feline family members is a valuable end point in 
itself, there is increasing recognition that by treat-
ing our pets, we stand to gain valuable insight 
into how we treat cancer in our own species.
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